Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
December 09, 2024 12:05 ET | Source: Tessera Therapeutics In vivo proof-of-concept…
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
December 09, 2024 12:00 ET | Source: Disc Medicine Inc Positive updates…
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT…
CRISPR Therapeutics Presents Data atthe 2024 American Society of Hematology (ASH) Annual Meeting
December 09, 2024 12:00 ET | Source: CRISPR Therapeutics AG -Preliminary data…
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 08, 2024 12:30 ET | Source: C4 Therapeutics, Inc. In Multiple…
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
December 07, 2024 12:00 ET | Source: Y-mAbs Therapeutics, Inc. NEW YORK,…